Tri Locum Partners LP
13F Reported Value
ⓘ$712.5M
Holdings
17
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Tri Locum Partners LP disclosed 17 positions worth $712.5M in its Form 13F-HR for Q1 2026, led by $JNJ (JOHNSON & JOHNSON) at 14.2% of the equity portfolio, followed by $ISRG and $TMO. During the quarter the fund opened 6 new positions and exited 4 — including a new stake in $ISRG and a full exit from $DHR. The portfolio is most concentrated in Healthcare (90.9% of disclosed assets). All figures are sourced directly from Tri Locum Partners LP’s Form 13F-HR filing with the SEC under CIK 1826434.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 72.8#214
Quality
$101.3M414,503 sh - 81.4#30
Quality
$70.6M153,250 sh - 63.7#678
Quality
$65.1M132,413 sh - 41.5
Quality
$58.4M255,332 sh - 76.6
Quality
$57.7M129,314 sh - 89.3
Quality
$56.8M61,795 sh - 25.4
Quality
$54.1M103,288 sh - 77.9
Quality
$43.8M698,158 sh - 80.1
Quality
$41.7M70,370 sh - —
Quality
$31.6M308,506 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 JOHNSON & JOHNSON$JNJ | 72.8#214 | $101.3M | 414,503 |
 INTUITIVE SURGICAL INC$ISRG | 81.4#30 | $70.6M | 153,250 |
 THERMO FISHER SCIENTIFIC INC.$TMO | 63.7#678 | $65.1M | 132,413 |
 Ascendis Pharma A/S$ASND | 41.5 | $58.4M | 255,332 |
 VERTEX PHARMACEUTICALS INC / MA$VRTX | 76.6 | $57.7M | 129,314 |
 ELI LILLY & Co$LLY | 89.3 | $56.8M | 61,795 |
 MADRIGAL PHARMACEUTICALS, INC.$MDGL | 25.4 | $54.1M | 103,288 |
 DEXCOM INC$DXCM | 77.9 | $43.8M | 698,158 |
 UNITED THERAPEUTICS Corp$UTHR | 80.1 | $41.7M | 70,370 |
 Nuvalent, Inc.$NUVL | — | $31.6M | 308,506 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Tri Locum Partners LP's 17 positions.
Showing top 10 of 17 holdings.
Sector Allocation
Healthcare
$647.5M
Technology
$65.1M
Full Holdings — Tri Locum Partners LP (Q1 2026)
All 17 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $JNJ | JOHNSON & JOHNSON | $101.3M | 14.2% | -31% | 72.8 |
| 2 | $ISRG | INTUITIVE SURGICAL INC | $70.6M | 9.9% | NEW | 81.4 |
| 3 | $TMO | THERMO FISHER SCIENTIFIC INC. | $65.1M | 9.1% | NEW | 63.7 |
| 4 | $ASND | Ascendis Pharma A/S | $58.4M | 8.2% | -4% | 41.5 |
| 5 | $VRTX | VERTEX PHARMACEUTICALS INC / MA | $57.7M | 8.1% | NEW | 76.6 |
| 6 | $LLY | ELI LILLY & Co | $56.8M | 8.0% | -2% | 89.3 |
| 7 | $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $54.1M | 7.6% | +20% | 25.4 |
| 8 | $DXCM | DEXCOM INC | $43.8M | 6.2% | +66% | 77.9 |
| 9 | $UTHR | UNITED THERAPEUTICS Corp | $41.7M | 5.9% | -42% | 80.1 |
| 10 | $NUVL | Nuvalent, Inc. | $31.6M | 4.4% | +0% | — |
| 11 |  $TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $30.8M | 4.3% | -29% | — |
| 12 |  $JAZZ | Jazz Pharmaceuticals plc | $30.0M | 4.2% | NEW | — |
| 13 |  $ARGX | ARGENX SE | $23.1M | 3.2% | -16% | — |
| 14 |  $TARS | Tarsus Pharmaceuticals, Inc. | $17.7M | 2.5% | NEW | 40.8 |
| 15 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $12.2M | 1.7% | -77% | 26.8 |
| 16 |  $AXSM | Axsome Therapeutics, Inc. | $10.5M | 1.5% | -69% | 36.6 |
| 17 |  $DFTX | Definium Therapeutics, Inc. | $7.0M | 1.0% | NEW | — |
New Positions (6)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Tri Locum Partners LP including:
Track Tri Locum Partners LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Tri Locum Partners LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Tri Locum Partners LP
13F Pro is an AI hedge fund tracker and stock research platform. For Tri Locum Partners LP (SEC CIK: 1826434), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Tri Locum Partners LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.